An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy

References

• Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. [ Internet] 2007;8:1–15. doi:10.1038/ni1443.
   Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. [ Internet] 2008;26:677–704. doi:10.1146/annurev.immunol.26.021607.090331.
   PubMed Web of Science ®Google Scholar
• Kuchroo JR, Hafler DA, Sharpe AH, Lucca LE. The double-edged sword: harnessing PD-1 blockade in tumor and autoimmunity. Sci Immunol. [ Internet] 2021;6:eabf4034. doi:10.1126/sciimmunol.abf4034.
   PubMed Web of Science ®Google Scholar
• Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, Sasmal DK, Huang J, Kim JM, Mellman I, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. [ Internet] 2017;355:1428–33. doi:10.1126/science.aaf1292.
   PubMed Web of Science ®Google Scholar
• Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. [ Internet] 2018;8:1069–86. doi:10.1158/2159-8290.CD-18-0367.
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. [ Internet] 2018;359:1350–55. doi:10.1126/science.aar4060.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science. [ Internet] 2015;348:56–61. doi:10.1126/science.aaa8172.
   PubMed Web of Science ®Google Scholar
• Xu JX, Maher VE, Zhang L, Tang S, Sridhara R, Ibrahim A, Kim G, Pazdur R. FDA approval summary: nivolumab in advanced renal cell carcinoma after anti-angiogenic therapy and exploratory predictive biomarker analysis. Oncologist. [ Internet] 2017;22:311–17. doi:10.1634/theoncologist.2016-0476.
   PubMed Web of Science ®Google Scholar
• Peters S, Kerr KM, Stahel R. PD-1 blockade in advanced NSCLC: a focus on pembrolizumab. Cancer Treat Rev. [ Internet] 2018;62:39–49. doi:10.1016/j.ctrv.2017.10.002.
   PubMed Web of Science ®Google Scholar
• Kasamon YL, de Claro RA, Wang Y, Shen YL, Farrell AT, Pazdur R. FDA approval summary: nivolumab for the treatment of relapsed or progressive classical Hodgkin lymphoma. Oncologist. [ Internet] 2017;22:585–91. doi:10.1634/theoncologist.2017-0004.
   PubMed Web of Science ®Google Scholar
• De Sousa Linhares A, Battin C, Jutz S, Leitner J, Hafner C, Tobias J, Wiedermann U, Kundi M, Zlabinger GJ, Grabmeier-Pfistershammer K, et al. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling. Sci Rep. [ Internet] 2019;9:11472. doi:10.1038/s41598-019-47910-1.
   PubMed Web of Science ®Google Scholar
• Zak KM, Grudnik P, Magiera K, Dömling A, Dubin G, Holak TA. Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1/PD-L2. Structure. 2017;25:1163–74. doi:10.1016/j.str.2017.06.011.
   PubMed Web of Science ®Google Scholar
• Wang J, Fei K, Jing H, Wu Z, Wu W, Zhou S, Ni H, Chen B, Xiong Y, Liu Y, et al. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. MAbs. [ Internet] 2019;11:1443–51. doi:10.1080/19420862.2019.1654303.
   PubMed Web of Science ®Google Scholar
• Richmond A, Su Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech. [ Internet] 2008;1:78–82. doi:10.1242/dmm.000976.
   PubMed Web of Science ®Google Scholar
• De La Rochere P, Guil-Luna S, Decaudin D, Azar G, Sidhu SS, Piaggio E. Humanized Mice for the Study of Immuno-Oncology. Trends Immunol. [ Internet] 2018;39:748–63. doi:10.1016/j.it.2018.07.001.
   PubMed Web of Science ®Google Scholar
• Fessas P, Lee H, Ikemizu S, Janowitz T. A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol. [ Internet] 2017;44:136–40. doi:10.1053/j.seminoncol.2017.06.002.
   PubMed Web of Science ®Google Scholar
• Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, Freeman GJ, Sharpe AH. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol. [ Internet] 2003;33:2706–16. doi:10.1002/eji.200324228.
   PubMed Web of Science ®Google Scholar
• Boder ET, Midelfort KS, Wittrup KD. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci U S A. [ Internet] 2000;97:10701–05. doi:10.1073/pnas.170297297.
   PubMed Web of Science ®Google Scholar
• Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD. Isolating and engineering human antibodies using yeast surface display. Nat Protoc. [ Internet] 2006;1:755–68. doi:10.1038/nprot.2006.94.
   PubMed Web of Science ®Google Scholar
• Ishino T, Wang M, Mosyak L, Tam A, Duan W, Svenson K, Joyce A, O’Hara DM, Lin L, Somers WS, et al. Engineering a monomeric Fc domain modality by N-glycosylation for the half-life extension of biotherapeutics. J Biol Chem. [ Internet] 2013;288:16529–37. doi:10.1074/jbc.M113.457689.
   PubMed Web of Science ®Google Scholar
• Van Deventer JA, Wittrup KD. Yeast surface display for antibody isolation: library construction, library screening, and affinity maturation. Methods Mol Biol. [ Internet] 2014;1131:151–81. doi:10.1007/978-1-62703-992-5_10.
   PubMedGoogle Scholar
• Lo M, Kim HS, Tong RK, Bainbridge TW, Vernes J-M, Zhang Y, Lin YL, Chung S, Dennis MS, Zuchero YJY, et al. Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice. J Biol Chem. [ Internet] 2017;292:3900–08. doi:10.1074/jbc.M116.767749.
   PubMed Web of Science ®Google Scholar
• Sivasubramanian A, Sircar A, Chaudhury S, Gray JJ. Toward high-resolution homology modeling of antibody Fv regions and application to antibody-antigen docking. Proteins. [ Internet] 2009;74:497–514. doi:10.1002/prot.22309.
   PubMed Web of Science ®Google Scholar
• Marze NA, Lyskov S, Gray JJ. Improved prediction of antibody VL-VH orientation. Protein Eng Des Sel. [ Internet] 2016;29:409–18. doi:10.1093/protein/gzw013.
   PubMed Web of Science ®Google Scholar
• Weitzner BD, Jeliazkov JR, Lyskov S, Marze N, Kuroda D, Frick R, Adolf-Bryfogle J, Biswas N, Dunbrack RL Jr, Gray JJ. Modeling and docking of antibody structures with Rosetta. Nat Protoc. [ Internet] 2017;12:401–16. doi:10.1038/nprot.2016.180.
   PubMed Web of Science ®Google Scholar
• Lyskov S, Chou F-C, Conchúir SÓ, Der BS, Drew K, Kuroda D, Xu J, Weitzner BD, Renfrew PD, Sripakdeevong P, et al. Serverification of molecular modeling applications: the Rosetta online server that includes everyone (ROSIE). PLoS One. [ Internet] 2013;8:e63906. doi:10.1371/journal.pone.0063906.
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Meesters JI, Priem P, de Jong RN, van den Bremer ETJ, van Kampen MD, Gerritsen AF, Schuurman J, Parren PWHI. Controlled Fab-arm exchange for the generation of stable bispecific IgG1. Nat Protoc. [ Internet] 2014;9:2450–63. doi:10.1038/nprot.2014.169.
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Meesters JI, Bunce M, Armstrong AA, Somani S, Nesspor TC, Chiu ML, Altintaş I, Verploegen S, Schuurman J, et al. Efficient generation of bispecific murine antibodies for pre-clinical investigations in syngeneic rodent models. Sci Rep. [ Internet] 2017;7:2476. doi:10.1038/s41598-017-02823-9.
   PubMed Web of Science ®Google Scholar
• Schmidt MM, Thurber GM, Wittrup KD. Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability. Cancer Immunol Immunother. [ Internet] 2008;57:1879–90. doi:10.1007/s00262-008-0518-1.
   PubMed Web of Science ®Google Scholar
• Lindauer A, Valiathan CR, Mehta K, Sriram V, de Greef R, Elassaiss-Schaap J, de Alwis DP. Translational pharmacokinetic/pharmacodynamic modeling of tumor growth inhibition supports dose-range selection of the anti-PD-1 antibody pembrolizumab. CPT Pharmacometrics Syst Pharmacol. [ Internet] 2017;6:11–20. doi:10.1002/psp4.12130.
   PubMedGoogle Scholar
• Li Z, Krippendorff B-F, Shah DK. Influence of Molecular size on the clearance of antibody fragments. Pharm Res. [ Internet] 2017;34:2131–41. doi:10.1007/s11095-017-2219-y.
   PubMed Web of Science ®Google Scholar
• Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmacol Sci. [ Internet] 2008;29:57–61. doi:10.1016/j.tips.2007.11.004.
   PubMed Web of Science ®Google Scholar
• Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther. [ Internet] 2009;8:2861–71. doi:10.1158/1535-7163.MCT-09-0195.
   PubMed Web of Science ®Google Scholar
• Selby MJ, Engelhardt JJ, Johnston RJ, L-S L, Han M, Thudium K, Yao D, Quigley M, Valle J, Wang C, et al. Preclinical development of ipilimumab and nivolumab combination immunotherapy: mouse tumor models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. PLoS One. [ Internet] 2016;11:e0161779. doi:10.1371/journal.pone.0161779.
   PubMed Web of Science ®Google Scholar
• Kurino T, Matsuda R, Terui A, Suzuki H, Kokubo T, Uehara T, Arano Y, Hisaka A, Hatakeyama H. Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models. J Immunother Cancer. [ Internet] 2020;8 doi:10.1136/jitc-2019-000400.
   PubMed Web of Science ®Google Scholar
• Moreno-Vicente J, Willoughby JE, Taylor MC, Booth SG, English VL, Williams EL, Penfold CA, Mockridge CI, Inzhelevskaya T, Kim J, et al. Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments. J Immunother Cancer. [ Internet] 2022;10. doi:10.1136/jitc-2021-003735.
   PubMed Web of Science ®Google Scholar
• Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. [ Internet] 2019;16:563–80. doi:10.1038/s41571-019-0218-0.
   PubMed Web of Science ®Google Scholar
• Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. [ Internet] 2012;39:67–86. doi:10.1007/s10928-011-9232-2.
   PubMed Web of Science ®Google Scholar
• Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev. [ Internet] 2008;60:1421–34. doi:10.1016/j.addr.2008.04.012.
   PubMed Web of Science ®Google Scholar
• Rudnick SI, Adams GP. Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm. [ Internet] 2009;24:155–61. doi:10.1089/cbr.2009.0627.
   PubMed Web of Science ®Google Scholar
• Tai Y, Wang Q, Korner H, Zhang L, Wei W. Molecular mechanisms of T cells activation by dendritic cells in autoimmune diseases. Front Pharmacol. [ Internet] 2018;9 doi:10.3389/fphar.2018.00642.
   Web of Science ®Google Scholar
• Riha P, Rudd CE. CD28 co-signaling in the adaptive immune response. Self Nonself. [ Internet] 2010;1:231–40. doi:10.4161/self.1.3.12968.
   PubMedGoogle Scholar
• Xia F, Qian C-R, Xun Z, Hamon Y, Sartre A-M, Formisano A, Mailfert S, Phelipot M-C, Billaudeau C, Jaeger S, et al. TCR and CD28 concomitant stimulation elicits a distinctive calcium response in naive T cells. Front Immunol. [ Internet] 2018;9:2864. doi:10.3389/fimmu.2018.02864.
   PubMed Web of Science ®Google Scholar
• Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV. FcγRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell. [ Internet] 2015;28:285–95. doi:10.1016/j.ccell.2015.08.004.
   PubMed Web of Science ®Google Scholar
• Arlauckas SP, Garris CS, Kohler RH, Kitaoka M, Cuccarese MF, Yang KS, Miller MA, Carlson JC, Freeman GJ, Anthony RM, et al. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med. [ Internet] 2017;9. doi:10.1126/scitranslmed.aal3604.
   PubMed Web of Science ®Google Scholar
• Tian T, Li Z. Targeting tim-3 in cancer with resistance to PD-1/PD-L1 blockade. Front Oncol. [ Internet] 2021;11:731175. doi:10.3389/fonc.2021.731175.
   PubMed Web of Science ®Google Scholar
• Coward J, Frentzas S, Mislang A, Gao B, Lemech C, Jin X, Li B, Wang M, Kwek KY, Zhou Y, et al. 427 Efficacy and safety of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with platinum-resistant/refractory epithelial ovarian cancer in a Phase 1 study. J Immunother Cancer. [ Internet] 2021;9. [cited 2022 Mar 8]. https://jitc.bmj.com/content/9/Suppl_2/A457.
   PubMed Web of Science ®Google Scholar
• Robert C. LAG-3 and PD-1 blockade raises the bar for melanoma. Nat Cancer. [ Internet] 2021;2:1251–53. doi:10.1038/s43018-021-00276-8.
   PubMedGoogle Scholar
• Pentcheva-Hoang T, Chen L, Pardoll DM, Allison JP. Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proc Natl Acad Sci U S A. [ Internet] 2007;104:17765–70. doi:10.1073/pnas.0708767104.
   PubMed Web of Science ®Google Scholar
• Riley JL. PD-1 signaling in primary T cells. Immunol Rev. [ Internet] 2009;229:114–25. doi:10.1111/j.1600-065X.2009.00767.x.
   PubMed Web of Science ®Google Scholar
• Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med. [ Internet] 2012;209:1201–17. doi:10.1084/jem.20112741.
   PubMed Web of Science ®Google Scholar
• Fenwick C, Loredo-Varela J-L, Joo V, Pellaton C, Farina A, Rajah N, Esteves-Leuenberger L, Decaillon T, Suffiotti M, Noto A, et al. Tumor suppression of novel anti-PD-1 antibodies mediated through CD28 costimulatory pathway. J Exp Med. [ Internet] 2019;216:1525–41. doi:10.1084/jem.20182359.
   PubMed Web of Science ®Google Scholar
• Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12. Immunity. [ Internet] 2018;49:1148–1161.e7. doi:10.1016/j.immuni.2018.09.024.
   PubMed Web of Science ®Google Scholar
• Bee C, Abdiche YN, Stone DM, Collier S, Lindquist KC, Pinkerton AC, Pons J, Rajpal A. Exploring the dynamic range of the kinetic exclusion assay in characterizing antigen-antibody interactions. PLoS One. [ Internet] 2012;7:e36261. doi:10.1371/journal.pone.0036261.
   PubMed Web of Science ®Google Scholar
• Sapidyne Instruments Inc. KinExA Manual [Internet]. 2019. [Accessed 20 Mar 2022]. https://www.sapidyne.com/uploads/1/1/8/8/118887362/um200r1_kinexa_manual.pdf
   Google Scholar
• Tisdale AW New protein engineering approaches for potentiating and studying antibody-based EGFR antagonism [Internet]. 2019 [cited 2022 Mar 22]: https://dspace.mit.edu/handle/1721.1/122521?show=full
   Google Scholar
• Momin N, Palmeri JR, Lutz EA, Jailkhani N, Mak H, Tabet A, Chinn MM, Kang BH, Spanoudaki V, Hynes RO, et al. Maximizing response to intratumoral immunotherapy in mice by tuning local retention. Nat Commun. [ Internet] 2022;13:109. doi:10.1038/s41467-021-27390-6.
   PubMed Web of Science ®Google Scholar
• Thurber GM, Dane Wittrup K. A mechanistic compartmental model for total antibody uptake in tumors. J Theor Biol. [ Internet] 2012;314:57–68. doi:10.1016/j.jtbi.2012.08.034.
   PubMed Web of Science ®Google Scholar
• Juneja VR, McGuire KA, Manguso RT, LaFleur MW, Collins N, Haining WN, Freeman GJ, Sharpe AH. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. [ Internet] 2017;214:895–904. doi:10.1084/jem.20160801.
   PubMed Web of Science ®Google Scholar
• Hinterneder J, Hopkinton MA Measuring PD-L1 and PD-1 expression in human cells with LANCE ultraTR-FRET.
   Google Scholar
• Zhang X, Schwartz J-CD, Guo X, Bhatia S, Cao E, Lorenz M, Cammer M, Chen L, Zhang Z-Y, Edidin MA, et al. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity. [ Internet] 2004;20:337–47. doi:10.1016/s1074-7613(04)00051-2.
   PubMed Web of Science ®Google Scholar
• Li K, Cheng X, Tilevik A, Davis SJ, Zhu C. In situ and in silico kinetic analyses of programmed cell death-1 (PD-1) receptor, programmed cell death ligands, and B7-1 protein interaction network. J Biol Chem. [ Internet] 2017;292:6799–809. doi:10.1074/jbc.M116.763888.
   PubMed Web of Science ®Google Scholar
• Burr ML, Sparbier CE, Chan Y-C, Williamson JC, Woods K, Beavis PA, Lam EYN, Henderson MA, Bell CC, Stolzenburg S, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. [ Internet] 2017;549:101–05. doi:10.1038/nature23643.
   PubMed Web of Science ®Google Scholar